文献速递肿瘤 PET/CT核素与放射性配体治疗

根治性前列腺切除术后PSMA阳性淋巴结复发患者全骨盆与半骨盆选择性淋巴结放疗的比较——一项回顾性多机构倾向性评分分析

Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-28

该多机构回顾性分析经倾向性评分匹配纳入102例(每组51例)根治性前列腺切除术后淋巴结复发患者,比较PSMA-PET/CT引导的全骨盆放疗(WPRT)与半骨盆放疗(HPRT)。两组生化复发无生存(p=.97)、无转移生存(p=.43)和无淋巴结复发生存(p=.43)均无显著差异;淋巴结转移灶加量、淋巴引流区放疗剂量>50 Gy EQD2α/β=1.5 Gy及同期雄激素剥夺治疗(ADT)与更长的BRFS显著相关。作者认为HPRT可获得与WPRT相似的肿瘤学结局,但WPRT组可能存在持续失衡导致更高进展风险,需进一步前瞻性研究。

要点

  • 倾向性评分匹配后102例(WPRT 51例、HPRT 51例),两组BRFS、MFS、NRFS均无显著差异。
  • 2年BRFS、MFS、NRFS:WPRT组61%、86%、88%,HPRT组57%、90%、82%。
  • 淋巴结转移灶加量、淋巴引流区剂量>50 Gy EQD2α/β=1.5 Gy及同期ADT与更长BRFS显著相关。

核心结论

  • 该分析呈现了HPRT在淋巴结复发前列腺癌患者中的结局,显示其可获得与WPRT相似的肿瘤学结局。
  • WPRT组患者可能因两组间部分持续失衡而处于更高的进展风险。
  • 作者认为需进一步前瞻性研究评估哪些患者亚组适合HPRT,以及HPRT是否带来临床显著的毒性降低。

研究设计与样本

  • 多机构回顾性数据集共273例因淋巴结复发接受骨盆放疗的患者(WPRT 214例、HPRT 59例),经倾向性评分匹配后102例(每组51例)纳入最终分析。
  • 采用Kaplan-Meier法计算生化复发无生存(BRFS,定义为PSA<放疗后最低值+0.2 ng/ml)、无转移生存(MFS)和无淋巴结复发生存(NRFS),并以log rank检验比较。

主要发现

  • 中位随访29个月;倾向性评分匹配后两组总体均衡,但WPRT组仍有显著更多患者存在额外局部复发和根治性前列腺切除术后生化持续。
  • 两组BRFS(p=.97)、MFS(p=.43)和NRFS(p=.43)均无显著差异。
  • 2年时WPRT组BRFS、MFS、NRFS分别为61%、86%、88%,HPRT组分别为57%、90%、82%。
  • 淋巴结转移灶加量、淋巴引流区放疗剂量>50 Gy EQD2α/β=1.5 Gy及同期ADT在单因素和多因素分析中均与更长BRFS显著相关。

关键数值与推荐

  • BRFS定义为PSA<放疗后最低值+0.2 ng/ml。
  • 淋巴引流区放疗剂量阈值>50 Gy EQD2α/β=1.5 Gy。
  • 2年BRFS:WPRT组61% vs HPRT组57%;2年MFS:WPRT组86% vs HPRT组90%;2年NRFS:WPRT组88% vs HPRT组82%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 为回顾性多机构分析。
  • 倾向性评分匹配后WPRT组仍有显著更多患者存在额外局部复发和根治性前列腺切除术后生化持续,两组间存在持续失衡。
  • 作者认为需进一步前瞻性研究评估适合HPRT的患者亚组及HPRT是否带来临床显著的毒性降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite growing evidence for bilateral pelvic radiotherapy (whole pelvis RT, WPRT) there is almost no data on unilateral RT (hemi pelvis RT, HPRT) in patients with nodal recurrent prostate cancer after prostatectomy. Nevertheless, in clinical practice HPRT is sometimes used with the intention to reduce side effects compared to WPRT. Prostate-specific membrane antigen positron emission tomography / computed tomography (PSMA-PET/CT) is currently the best imaging modality in this clinical situation. This analysis compares PSMA-PET/CT based WPRT and HPRT. METHODS: A propensity score matching was performed in a multi-institutional retrospective dataset of 273 patients treated with pelvic RT due to nodal recurrence (214 WPRT, 59 HPRT). In total, 102 patients (51 in each group) were included in the final analysis. Biochemical recurrence-free survival (BRFS) defined as prostate specific antigen (PSA) < post-RT nadir + 0.2ng/ml, metastasis-free survival (MFS) and nodal recurrence-free survival (NRFS) were calculated using the Kaplan-Meier method and compared using the log rank test. RESULTS: Median follow-up was 29 months. After propensity matching, both groups were mostly well balanced. However, in the WPRT group there were still significantly more patients with additional local recurrences and biochemical persistence after prostatectomy. There were no significant differences between both groups in BRFS (p = .97), MFS (p = .43) and NRFS (p = .43). After two years, BRFS, MFS and NRFS were 61%, 86% and 88% in the WPRT group and 57%, 90% and 82% in the HPRT group, respectively. Application of a boost to lymph node metastases, a higher RT dose to the lymphatic pathways (> 50 Gy EQD2α/β=1.5 Gy) and concomitant androgen deprivation therapy (ADT) were significantly associated with longer BRFS in uni- and multivariate analysis. CONCLUSIONS: Overall, this analysis presents the outcome of HPRT in nodal recurrent prostate cancer patients and shows that it can result in a similar oncologic outcome compared to WPRT. Nevertheless, patients in the WPRT may have been at a higher risk for progression due to some persistent imbalances between the groups. Therefore, further research should prospectively evaluate which subgroups of patients are suitable for HPRT and if HPRT leads to a clinically significant reduction in toxicity.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Trapp C, Aebersold DM, Belka C, et al. Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. Eur J Nucl Med Mol Imaging. 2024. PMID: 38940843. doi:10.1007/s00259-024-06802-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。